Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9616 posts found.

whats_up_doc

Lemtrada shows clinical efficacy in multiple sclerosis in 10-year follow-up data

April 20, 2016 Research and Development, Sales and Marketing Lemtrada, Sanofi, alemtuzumab, multiple sclerosis, sanofi genzyme

Sanofi Genzyme has presented 10-year follow-up data on Lemtrada (alemtuzumab) which points to its efficacy in patients with relapsing-remitting multiple …
News

Bayer says its Xarelto shows lower risk of stroke, brain haemorrhage for irregular heart rhythm condition vs BMS’ Coumadin

April 19, 2016 Manufacturing and Production, Research and Development Bayer, Bristol-Myers Squibb, anti blood-clot, drug trial

New trials for anti blood-clotting drug Xarelto (rivaroxaban) showed lower risk of stroke and haemorrhage in patients with irregular heart …
News
bms_building_uk

Bristol-Myers Squibb’s Opdivo shows positive results in early stage trials for advanced skin cancer

April 19, 2016 Manufacturing and Production, Research and Development Bristol-Myers Squibb, drug trial, immuno-therapy, oncology, opdivo

New data for Bristol-Myers Squibb’s (NYSE: BMY) Opdivo to treat advanced melanoma showed overall survival of five years in 34% patients, …
News
opdivo_1

Opdivo shows biggest survival increase for head and neck cancer in 20 years in Phase III trials

April 19, 2016 Research and Development, Sales and Marketing Bristol-Myers Squibb, Cancer, blockbuster, head and neck cancer, nivolumab, oncology, opdivo, potential, squamous

Opdivo (nivolumab) showed the biggest increase in survival for patients with head and neck cancer for 20 years, according to …
News
eli_lilly_logo

Eli Lilly drops development of diabetes drug in Phase III

April 19, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Eli Lilly, Transition Therapeutics, diabetes, drug trial

US drugmaker Eli Lilly (NYSE: LLY) has pulled out of the partnership with Transition Therapeutics (TSX: TTH) to develop its …
News
keytruda1

MSD receives fourth Breakthrough Therapy Designation for Keytruda

April 19, 2016 Manufacturing and Production, Research and Development Breakthrough Therapy Designation, FDA, Hodgkin lymphoma, MSD, Merck, breakthrough designation, breakthrough therapy, keytruda

MSD (NYSE: MRK) has announced that the US Food and Drug Administration has granted Breakthrough Therapy Designation to Keytruda (pembrolizumab) …
News
clinicaltrial

FDA rejects Chiasma’s new drug application for therapy to treat rare growth disorder

April 18, 2016 Research and Development, Sales and Marketing Chiasma Inc, US FDA, drug trial, rare disease

Shares in Chiasma Inc (Nasdaq: CHMA) plunged to more than halve on the Nasdaq Monday as the company reported the …
News
novo_corp_hq2

Novo unveils new research grant to mark World Haemophilia Day

April 18, 2016 Medical Communications, Research and Development, Sales and Marketing Novo Nordisk, grant, haemophilia, hero, world haemophilia day

Novo Nordisk has marked World Haemophilia Day 2016 with the announcement of a new research grant aimed at supporting and …
News
tablet_production_2

British Biosimilars Association launches in UK

April 18, 2016 Manufacturing and Production, Research and Development, Sales and Marketing ABPI, Napp, bba, bgma, british biosimilars association

A new industry body, the British Biosimilars Association, has been formally launched today with the sole focus of increasing the …
News
stocks1

Weekly Movers: Valeant, Depomed, Intercept Pharma, Insys Therapeutics and more…

April 18, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Depomed, Intercept Pharma, Relypsa, Share price, Stock Movement, Valeant, stock market

Troubles don’t seem to go away for Canada-based Valeant Pharma (NYSE: VRX) with news of a probable sale doing the …
Feature
clinicaltrial1

Sosei‘s Heptares And Kymab to collaborate on developing new antibody therapeutics

April 18, 2016 Research and Development, Sales and Marketing Heptares Therapeutics, Kymab Ltd, Sosei Group, collaboration, drug development, immuno-oncology

Japan’s Sosei Group Corp (TSE: 4565) has signed a collaboration deal with Kymab Ltd to develop and market novel antibody …
News
paris

Clinical trial initiated to help Paris attacks victims with PTSD

April 15, 2016 Medical Communications, Research and Development France, clinical trial, mcgill, mcgill university, terror attacks

Victims of the recent Paris terror attacks have been offered the opportunity to take part in a clinical trial, organised …
News
hospital

Repros Therapeutics says positive results from Phase II trial of uterine fibroids drug; shares jump

April 15, 2016 Medical Communications, Research and Development Repros Therapeutics, Shares, US FDA, drug trial, uterine fibroids

Shares in Repros Therapeutics (Nasdaq: RPRX) surged to close over 18% Thursday after the company announced positive mid-stage trial results …
News
shutterstock_211705468

US annual spending on drugs rose 12.2% in 2015 – IMS

April 15, 2016 Medical Communications, Research and Development, Sales and Marketing IMS Health, drug spending

The total US spending on prescription drugs rose 12.2% to almost $425 billion in 2015 on the back of new …
News
cancer_cells

Roche’s cholesterol-lowering drug candidate shows promise in fighting prostate cancer

April 15, 2016 Medical Communications, Research and Development RO 48-9071, Roche, cholesterol, drug, missouri, oncology, university

Researchers from the University of Missouri have found that a compound developed by Roche Pharmaceuticals for the treatment of high …
News
The Gateway to Local Adoption Series

Latest content

Japanese pharma outsources earlier as peptide development challenges grow

April 29, 2026

Study suggests phospholipid therapy may impact fatty liver disease outcomes

April 29, 2026

FDA signals support for development of psychedelic therapies in mental healthmental health

April 28, 2026

New web series explores path from ophthalmic research to patient access

April 28, 2026

EMA backs plozasiran for rare lipid disorder with high pancreatitis risk

April 27, 2026